WS #1805

The Strait of Hormuz blockade is escalating into a broader regional conflict, with new military and diplomatic developments amplifying energy supply risks. Qatar has reportedly ordered Iranian military attaches to leave within 24 hours, while Saudi Arabia's foreign minister stated that 'military options remain available,' indicating heightened tensions that could expand beyond tit-for-tat strikes. Concurrently, the Pentagon is considering using Marines from Japan to seize islands south of Iran to force navigation restoration, as reported by The Wall Street Journal and corroborated across multiple Bluesky posts, suggesting imminent U.S. military action. These moves, combined with Iran's proposal to impose tolls on shipping through the strait and threats to 'set fire' to ships, signal a hardening blockade that analysts warn could surpass the oil shocks of 1973 or 1979 if prolonged. Global markets are reacting with a pronounced risk-off sentiment, driven by the geopolitical and energy shocks. Equity indices show significant declines: the U.S. Dow is down 1.63%, S&P 500 at 6,624.70 (-1.36%), Nasdaq -1.46%, with the VIX surging 12.16% to 25.09. International markets are also under pressure, with Japan's Nikkei falling 3.38% to 53,372.53, Europe's STOXX 600 down 0.75%, DAX -0.96%, and India's Sensex dropping 3.26% to 74,207.24. Energy prices are spiking, with oil above $100 and TTF gas up 13.7% to 62.15, reflecting supply concerns. Additionally, Russia's Energy Ministry warned that a fuel export ban may be introduced preventively in case of high prices, adding another layer of supply disruption risk. Corporate news is secondary but includes notable earnings and guidance updates. Accenture reported strong Q2 results with EPS of $2.93 beating estimates of $2.84 and sales of $18.044B beating $17.843B, while raising full-year EPS guidance, which could support its stock. Eli Lilly announced positive Phase 3 results for its diabetes treatment retatrutide, showing significant weight loss of up to 16.8%, potentially boosting its pharmaceutical prospects. Pfizer reported topline Phase 3 results for TALZENNA in combination with XTANDI improving radiographic progression-free survival in metastatic prostate cancer, meeting its primary endpoint. However, other earnings like Titan Machinery's miss and downgrades such as Evercore ISI Group downgrading CSX to In-Line add mixed signals. The overall signal points to sustained volatility in energy and equity markets, with specific tickers like oil majors, shipping, and transportation stocks likely affected. The broadening conflict and military posturing increase the likelihood of prolonged supply disruptions, keeping upward pressure on energy prices and downward pressure on risk assets in the near term.